vs
STANDARD BIOTOOLS INC.（LAB）与TRANSCONTINENTAL REALTY INVESTORS INC（TCI）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是TRANSCONTINENTAL REALTY INVESTORS INC的1.6倍（$19.6M vs $12.1M），TRANSCONTINENTAL REALTY INVESTORS INC净利率更高（68.8% vs -177.4%，领先246.2%），TRANSCONTINENTAL REALTY INVESTORS INC同比增速更快（2.3% vs -11.5%），过去两年TRANSCONTINENTAL REALTY INVESTORS INC的营收复合增速更高（0.7% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
跨大陆房地产投资者公司（TCI）是一家总部位于美国的房地产投资企业，持有并运营涵盖住宅、商业及综合用途的多元化物业组合，业务覆盖美国核心区域市场，通过战略收购、高效资产管理和定制化租赁方案实现长期价值增长。
LAB vs TCI — 直观对比
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $12.1M |
| 净利润 | $-34.7M | $8.3M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | -28.9% |
| 净利率 | -177.4% | 68.8% |
| 营收同比 | -11.5% | 2.3% |
| 净利润同比 | -28.8% | 7577.8% |
| 每股收益（稀释后） | $-0.09 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $12.1M | ||
| Q3 25 | $19.6M | $12.8M | ||
| Q2 25 | $21.8M | $12.2M | ||
| Q1 25 | $40.8M | $12.0M | ||
| Q4 24 | — | $11.8M | ||
| Q3 24 | $22.1M | $11.6M | ||
| Q2 24 | $22.5M | $11.8M | ||
| Q1 24 | $45.5M | $11.9M |
| Q4 25 | — | $8.3M | ||
| Q3 25 | $-34.7M | $724.0K | ||
| Q2 25 | $-33.5M | $169.0K | ||
| Q1 25 | $-26.0M | $4.6M | ||
| Q4 24 | — | $108.0K | ||
| Q3 24 | $-26.9M | $1.7M | ||
| Q2 24 | $-45.7M | $1.5M | ||
| Q1 24 | $-32.2M | $2.5M |
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
| Q4 25 | — | -28.9% | ||
| Q3 25 | -168.5% | -10.9% | ||
| Q2 25 | -118.1% | -6.8% | ||
| Q1 25 | -80.8% | -5.3% | ||
| Q4 24 | — | -14.3% | ||
| Q3 24 | -120.9% | -14.4% | ||
| Q2 24 | -134.5% | -9.2% | ||
| Q1 24 | -132.2% | -11.2% |
| Q4 25 | — | 68.8% | ||
| Q3 25 | -177.4% | 5.6% | ||
| Q2 25 | -153.7% | 1.4% | ||
| Q1 25 | -63.8% | 38.5% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | -122.0% | 14.7% | ||
| Q2 24 | -203.3% | 12.7% | ||
| Q1 24 | -70.6% | 21.4% |
| Q4 25 | — | $0.97 | ||
| Q3 25 | $-0.09 | $0.08 | ||
| Q2 25 | $-0.09 | $0.02 | ||
| Q1 25 | $-0.07 | $0.53 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | $-0.07 | $0.20 | ||
| Q2 24 | $-0.12 | $0.17 | ||
| Q1 24 | $-0.27 | $0.30 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $89.0M |
| 总债务越低越好 | — | $210.8M |
| 股东权益账面价值 | $399.7M | $846.7M |
| 总资产 | $539.6M | $1.1B |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
| Q4 25 | — | $89.0M | ||
| Q3 25 | $129.4M | $82.7M | ||
| Q2 25 | $158.6M | $73.5M | ||
| Q1 25 | $150.9M | $88.6M | ||
| Q4 24 | — | $99.7M | ||
| Q3 24 | $210.6M | $131.6M | ||
| Q2 24 | $269.8M | $127.5M | ||
| Q1 24 | $287.1M | $130.8M |
| Q4 25 | — | $210.8M | ||
| Q3 25 | — | $223.5M | ||
| Q2 25 | — | $212.4M | ||
| Q1 25 | — | $198.2M | ||
| Q4 24 | — | $181.9M | ||
| Q3 24 | $55.2M | $180.3M | ||
| Q2 24 | $55.1M | $177.4M | ||
| Q1 24 | $55.0M | $178.3M |
| Q4 25 | — | $846.7M | ||
| Q3 25 | $399.7M | $838.4M | ||
| Q2 25 | $424.5M | $837.7M | ||
| Q1 25 | $454.6M | $837.3M | ||
| Q4 24 | — | $832.3M | ||
| Q3 24 | $489.3M | $832.2M | ||
| Q2 24 | $510.3M | $830.4M | ||
| Q1 24 | $577.3M | $828.9M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | $539.6M | $1.1B | ||
| Q2 25 | $557.0M | $1.1B | ||
| Q1 25 | $579.6M | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $681.5M | $1.1B | ||
| Q2 24 | $708.7M | $1.0B | ||
| Q1 24 | $777.7M | $1.0B |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | 0.11× | 0.22× | ||
| Q2 24 | 0.11× | 0.21× | ||
| Q1 24 | 0.10× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-2.9M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | -0.35× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $-2.9M | ||
| Q3 25 | $-22.2M | $8.2M | ||
| Q2 25 | $-20.7M | $-2.9M | ||
| Q1 25 | $-30.3M | $-7.4M | ||
| Q4 24 | — | $1.3M | ||
| Q3 24 | $-27.9M | $13.7M | ||
| Q2 24 | $-39.0M | $-511.0K | ||
| Q1 24 | $-62.5M | $3.9M |
| Q4 25 | — | — | ||
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | — | -0.35× | ||
| Q3 25 | — | 11.28× | ||
| Q2 25 | — | -17.24× | ||
| Q1 25 | — | -1.61× | ||
| Q4 24 | — | 12.13× | ||
| Q3 24 | — | 8.03× | ||
| Q2 24 | — | -0.34× | ||
| Q1 24 | — | 1.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
TCI
暂无分部数据
